Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines - Brody, Tom, PhD (Consultant for Second Genome, Inc. (Crohn's disease), Rigel Pharmaceuticals (platelet disorder), PrimeGen Biotech (stem cell therapy), Regeneron Pharmaceuticals (broadly neutralizing antibodies for HIV), and Biogen IDEC (multiple sclerosi - Libros - Elsevier Science Publishing Co Inc - 9780128042175 - 14 de marzo de 2016
En caso de que portada y título no coincidan, el título será el correcto

Brody, Tom, PhD (Consultant for Second Genome, Inc. (Crohn's disease), Rigel Pharmaceuticals (platelet disorder), PrimeGen Biotech (stem cell therapy), Regeneron Pharmaceuticals (broadly neutralizing antibodies for HIV), and Biogen IDEC (multiple sclerosi
Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines 2.º edición

Precio
$ 96,49
sin IVA

Pedido desde almacén remoto

Entrega prevista 18 - 30 de jun.

Nuestros clientes opinan:

Política de devolución de 14 días conforme a la legislación europea de protección de los consumidores
Mejor valorado en Trustpilot
Añadir a tu lista de deseos de iMusic

896 pages, Approx. 100 illustrations

Medios de comunicación Libros     Hardcover Book   (Libro con lomo y cubierta duros)
Publicado 14 de marzo de 2016
ISBN13 9780128042175
Editores Elsevier Science Publishing Co Inc
Páginas 896
Dimensiones 243 × 201 × 49 mm   ·   1,97 kg

Mas por Brody, Tom, PhD (Consultant for Second Genome, Inc. (Crohn's disease), Rigel Pharmaceuticals (platelet disorder), PrimeGen Biotech (stem cell therapy), Regeneron Pharmaceuticals (broadly neutralizing antibodies for HIV), and Biogen IDEC (multiple sclerosi

Mostrar todo

Mere med samme udgiver

Ver todo de Brody, Tom, PhD (Consultant for Second Genome, Inc. (Crohn's disease), Rigel Pharmaceuticals (platelet disorder), PrimeGen Biotech (stem cell therapy), Regeneron Pharmaceuticals (broadly neutralizing antibodies for HIV), and Biogen IDEC (multiple sclerosi ( Ej. Hardcover Book )